WesBanco Bank’s Guardant Health GH Stock Holding History

WesBanco Bank’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,016	Closed	-$308K	–	692
2025 Q4	$308K	Buy	+3,016	New	+$270K	0.01%	567
2025 Q2	–	Sell	-12,900	Closed	-$550K	–	657
2025 Q1	$550K	Hold	12,900	–	–	0.02%	415
2024 Q4	$394K	Hold	12,900	–	–	0.01%	469
2024 Q3	$296K	Buy	+12,900	New	+$365K	0.01%	523

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WesBanco Bank's GH Position: Q1 2026 in Review

WesBanco Bank sold out of Guardant Health (GH) in Q1 2026, closing a stake of 3,016 shares — an estimated $308K sold.

WesBanco Bank first reported a position in GH in Q3 2024 and held it in 4 quarters. The position peaked at $550K in Q1 2025. 482 funds tracked by Wall St. Rank hold GH as of Q1 2026.

WesBanco Bank reported no remaining Guardant Health position as of Q1 2026 after selling out during the quarter.
WesBanco Bank sold 3,016 Guardant Health shares in Q1 2026, an estimated $308K.
WesBanco Bank first reported a position in Guardant Health in Q3 2024 and held it in 4 quarters.
WesBanco Bank's Guardant Health position peaked at $550K in Q1 2025.
482 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on WesBanco Bank's 13F filing for Q1 2026, filed 21 Apr 2026.